The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Jul 2017 07:00

RNS Number : 5054M
Silence Therapeutics PLC
31 July 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Silence Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Richard Griffiths and controlled undertakings

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

27 July 2017

6. Date on which issuer notified:

28 July 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

 > 25,26

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B9GTXM62

17,458,481

17,458,481

18,838,695

18,838,695

26.92%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

18,838,695

26.92%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Blake Holdings Limited

7,550,731

Seren Investment Management Limited

8,223,507

Oak Trust Limited

182,837

Richard Griffiths - indirect holdings

692,153

Sarossa Plc

2,189,467

Total

18,838,695

 

 

The above undertakings are all controlled by Richard Griffiths

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

James Sutcliffe

15. Contact telephone number:

+ 44 1534 719 761

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLURSVRBRABOAR
Date   Source Headline
20th Sep 201712:02 pmRNSPrice Monitoring Extension
13th Sep 201712:07 pmRNSSecond Price Monitoring Extn
13th Sep 201712:02 pmRNSPrice Monitoring Extension
11th Sep 20171:30 pmRNSFurther Strengthens US Patent Estate
8th Sep 201712:07 pmRNSSecond Price Monitoring Extn
8th Sep 201712:02 pmRNSPrice Monitoring Extension
6th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
4th Sep 20177:00 amRNSNotice of Interim Results
23rd Aug 20177:00 amRNSSave the Date: Capital Markets Event 14 November
17th Aug 20174:05 pmRNSReplacement - Holding(s) in Company
17th Aug 20172:02 pmRNSDirector/PDMR Shareholding
15th Aug 20177:00 amRNSTwo further US patents to be granted
3rd Aug 20177:00 amRNSDirector/PDMR Shareholding
31st Jul 201711:43 amRNSDirector/PDMR Shareholding
31st Jul 20177:00 amRNSHolding(s) in Company
31st Jul 20177:00 amRNSUS patent to be granted
27th Jul 20172:43 pmRNSLicensee Quark Announces Positive AKI Results
24th Jul 20177:00 amRNSPresenting at Canaccord Genuity Growth Conference
24th Jul 20177:00 amRNSSilence Strengthens US Patent Estate
14th Jul 20177:00 amRNSCEO Ali Mortazavi appointed Chairman of Ultromics
10th Jul 20177:41 amRNSIP update
3rd Jul 20172:34 pmRNSIssue of claim in the UK High Courts
3rd Jul 20177:00 amRNSChange of Adviser
29th Jun 201711:47 amRNSHolding(s) in Company
6th Jun 20177:00 amRNSResult of AGM
1st Jun 20177:00 amRNSHiring of Chief Operating Officer
30th May 20177:00 amRNSSilence Continued Expansion of IP
16th May 20177:00 amRNSSignificant Expansion of Intellectual Property
4th May 201712:05 pmRNSNotice of AGM and Publication of Annual Report
3rd May 20177:00 amRNSSilence Therapeutics Presents New Data
12th Apr 20171:30 pmRNSAdditional Listing
3rd Apr 20177:00 amRNSGrant of Share Options to Directors
28th Mar 20177:00 amRNSPreliminary Results for the year to 31 Dec 2016
8th Mar 20177:00 amRNSNotice of Results
13th Jan 20172:03 pmRNSMinority Stake in Arrowhead Pharmaceuticals
9th Jan 20177:00 amRNSAcquisition of Minority Stake in Arrowhead
20th Dec 20167:00 amRNSSilence announces Quark arbitration resolution
15th Nov 20167:00 amRNSCRISPR/Cas9 Gene Editing Data
27th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSNotice of Results
5th Sep 20167:00 amRNSAppointment of CSO and Non-Executive Director
18th Jul 20167:00 amRNSDirector/PDMR Shareholding
17th Jun 20163:48 pmRNSResult of AGM
1st Jun 20162:35 pmRNSHolding(s) in Company
24th May 20167:00 amRNSBoard Changes, Advisory Board and Notice of AGM
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
18th Apr 20166:09 pmRNSDirector/PDMR Shareholding
18th Apr 20167:00 amRNSGrant of share options to Chief Executive
5th Apr 20167:00 amRNSAtu027 Update
5th Apr 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.